Prognostication of Hepatocellular Carcinoma Using Artificial Intelligence.

Journal: Korean journal of radiology
Published Date:

Abstract

Hepatocellular carcinoma (HCC) is a biologically heterogeneous tumor characterized by varying degrees of aggressiveness. The current treatment strategy for HCC is predominantly determined by the overall tumor burden, and does not address the diverse prognoses of patients with HCC owing to its heterogeneity. Therefore, the prognostication of HCC using imaging data is crucial for optimizing patient management. Although some radiologic features have been demonstrated to be indicative of the biologic behavior of HCC, traditional radiologic methods for HCC prognostication are based on visually-assessed prognostic findings, and are limited by subjectivity and inter-observer variability. Consequently, artificial intelligence has emerged as a promising method for image-based prognostication of HCC. Unlike traditional radiologic image analysis, artificial intelligence based on radiomics or deep learning utilizes numerous image-derived quantitative features, potentially offering an objective, detailed, and comprehensive analysis of the tumor phenotypes. Artificial intelligence, particularly radiomics has displayed potential in a variety of applications, including the prediction of microvascular invasion, recurrence risk after locoregional treatment, and response to systemic therapy. This review highlights the potential value of artificial intelligence in the prognostication of HCC as well as its limitations and future prospects.

Authors

  • Subin Heo
    Department of Radiology, Ajou University School of Medicine, Wonchon-Dong, Yeongtong-Gu, Suwon, 443-380, South Korea.
  • Hyo Jung Park
    Department of Radiology and Research Institute of Radiology, Asan Image Metrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Seung Soo Lee
    From the Department of Computer Science, Hanyang University, Seoul, Republic of Korea (K.J.C.); Department of Radiology and Research Institute of Radiology (J.K.J., S.S.L., Y.S.S., W.H.S., H.S.K., J.Y., J.H.K., S.Y.K.) and Department of Diagnostic Pathology (E.S.Y.), Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea; Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (J.Y.C.); Department of Radiology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea (Y.L.); and Department of Radiology, Hanyang University Medical Center, Hanyang University School of Medicine, Seoul, Korea (B.K.K.).